Exagen Ownership

XGN Stock  USD 3.44  0.01  0.29%   
Exagen holds a total of 17.64 Million outstanding shares. Over half of Exagen's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2013-03-31
Previous Quarter
18.2 M
Current Value
18.3 M
Avarage Shares Outstanding
8.3 M
Quarterly Volatility
8.2 M
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Exagen in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Exagen, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Exagen Stock Ownership Analysis

About 27.0% of the company outstanding shares are owned by insiders. The book value of Exagen was at this time reported as 0.73. The company recorded a loss per share of 0.94. Exagen Inc had not issued any dividends in recent years. Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Exagen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 219 people. For more information please call John Aballi at 760 560 1501 or visit https://www.exagen.com.

Exagen Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Exagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exagen Inc backward and forwards among themselves. Exagen's institutional investor refers to the entity that pools money to purchase Exagen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-12-31
98.1 K
Palumbo Wealth Management Llc2024-12-31
86.7 K
Ubs Group Ag2024-12-31
64.2 K
Nantahala Capital Management, Llc2024-12-31
62.1 K
Penbrook Management Llc2024-12-31
44.6 K
Wasatch Advisors Lp2024-12-31
43 K
Creative Planning Inc2024-12-31
35.5 K
State Street Corp2024-12-31
33.7 K
Blackrock Inc2024-12-31
33.4 K
Rtw Investments, Llc2024-12-31
1.5 M
Cowen And Company, Llc2024-09-30
891.4 K
Note, although Exagen's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Exagen Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exagen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Exagen Outstanding Bonds

Exagen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Exagen Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Exagen bonds can be classified according to their maturity, which is the date when Exagen Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Exagen Corporate Filings

25th of February 2025
Other Reports
ViewVerify
29th of January 2025
Other Reports
ViewVerify
8K
13th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
12th of December 2024
An amended filing to the original Schedule 13G
ViewVerify

Pair Trading with Exagen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.

Moving against Exagen Stock

  0.44CUE Cue BiopharmaPairCorr
  0.35INAB In8bio IncPairCorr
  0.34GANX Gain TherapeuticsPairCorr
  0.33DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.94)
Revenue Per Share
3.088
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.18)
Return On Equity
(0.84)
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.